MHIP
GILD icon

Mountain Hill Investment Partners’s Gilead Sciences GILD Stock Holding History

Mountain Hill Investment Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$24.5K – 224
2025
Q4 		$24.5K Hold
200
– – 0.02% 89
2025
Q3 		$22.2K Buy
+200
New +$22.7K 0.02% 95

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Mountain Hill Investment Partners's GILD Position: Q1 2026 in Review

Mountain Hill Investment Partners sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 200 shares — an estimated $24.5K sold.

Mountain Hill Investment Partners first reported a position in GILD in Q3 2025 and held it in 2 quarters. The position peaked at $24.5K in Q4 2025. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Mountain Hill Investment Partners reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • Mountain Hill Investment Partners sold 200 Gilead Sciences shares in Q1 2026, an estimated $24.5K.
  • Mountain Hill Investment Partners first reported a position in Gilead Sciences in Q3 2025 and held it in 2 quarters.
  • Mountain Hill Investment Partners's Gilead Sciences position peaked at $24.5K in Q4 2025.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Mountain Hill Investment Partners's 13F filing for Q1 2026, filed 1 May 2026.